Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL325745 | 0.88 | DYRK1A (0.42) | MKNK2KMT2ADYRK1AP2RX3 | |
| SCHEMBL14275291 | 0.82 | MKNK2 (0.40) | MKNK2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL326895 | 0.81 | PTPN11 (0.40) | MKNK2KLKB1MEN1KMT2AALDH1A1 | |
| SCHEMBL326115 | 0.81 | CA12 (0.44) | MTNR1AMTNR1BMKNK2MEN1KMT2A | |
| SCHEMBL325790 | 0.81 | MKNK2 (0.41) | MTNR1AMTNR1BMKNK2MEN1KMT2A | |
| SCHEMBL7652554 | 0.77 | NPC1 (0.58) | MEN1KMT2AALDH1A1MAPTL3MBTL1 | |
| SCHEMBL14463668 | 0.76 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL325145 | 0.76 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL14900195 | 0.74 | ALDH1A1 (0.48) | MTNR1AMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL12530438 | 0.74 | PROKR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362247-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-29 | — | — | US | disclosed |
| US-20120129862-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-05-24 | — | — | US | disclosed |
| US-20110319418-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | disclosed |
| US-7968710-B2 | Gastrointestinal disorders;inflammatory bowel disorders; gastroesophageal reflux; constipation | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-28 | — | — | US | disclosed |
| US-20080045535-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045535-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | MTNR1A 139/4885MTNR1B 59/4885MKNK2 432/4885 |
| US-20120129862-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | MTNR1A 69/4885MTNR1B 43/4885MKNK2 752/4885 |
| US-20110319418-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | PROKR1, OPRL1, PROKR2 | MTNR1A 75/4885MTNR1B 47/4885MKNK2 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.